ribonuclease A family member 9 (inactive)Genealiases: HEL128 · RAK1 · h461
Q-omics provides the consensus-scored RNASE9 profile across patient tissues and cancer cell-line models. RNASE9 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNASE9 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, RNASE9 RNA expression shows 6,258 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUAD, and STAD as cancer lineages where RNASE9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE9 survival associations across molecular data types. RNASE9 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE9 RNA expression–survival associations across cancer types. High RNASE9 expression shows unfavorable associations in KIRC, MESO, CESC, ESCA, COAD and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNASE9 RNA expression.
This table summarizes RNASE9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNASE9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE9 shows higher tumor expression in LUAD, KIRC and HNSC. The LUAD box plot shows higher RNASE9 RNA expression in tumor versus normal tissue (log2 FC = +0.008, t-test p = .017).
This table shows molecular features associated with RNASE9 in patient tissues and cancer cell lines. In patient samples, RNASE9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
